Bempedoic Acid Cuts Ischemic Stroke Risk 22%, Shows Similar MACE Benefit in Autoimmune/Inflammatory Disease Patients
Post-hoc CLEAR Outcomes analyses showed bempedoic acid cut ischemic stroke risk by 22% versus placebo in statin-intolerant patients and delivered similar MACE reductions in high-risk autoimmune or inflammatory disease patients. Presentation at ACC.26 underscores NEXLETOL’s effective cardiovascular risk reduction for patients unable to tolerate statins.
1. Key Stroke Risk Reduction
CLEAR Outcomes post-hoc analysis included 293 fatal or nonfatal stroke events (90% ischemic) and found bempedoic acid reduced ischemic stroke risk by 22% versus placebo among statin-intolerant patients, demonstrating a statistically significant benefit in this subgroup.
2. MACE Outcomes in Autoimmune/Inflammatory Disease
Approximately 10% of the 13,970 participants had prior autoimmune or inflammatory diseases; these high-risk patients experienced comparable major adverse cardiovascular event reductions with bempedoic acid as patients without such conditions, indicating consistent efficacy across diverse populations.
3. Clinical and Market Implications
Presentation of these analyses at ACC.26 reinforces NEXLETOL’s clinical value for cardiovascular risk reduction in statin-intolerant and high-risk groups, potentially supporting wider guideline incorporation and driving greater adoption among cardiologists treating vulnerable patients.